Literature DB >> 7676462

Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors.

R R Maronpot1, T Fox, D E Malarkey, T L Goldsworthy.   

Abstract

The mouse liver is a frequent target organ for chemical carcinogenesis (Huff et al., 1988, 1991; Gold et al., 1989) and tumor development exhibits preferential strain sensitivity (Dragani et al., 1992; Drinkwater and Bennett, 1991). In some reports a positive correlation has been observed between the degree of spontaneous liver tumor incidence and the propensity to develop liver tumors after treatment with chemical carcinogens (Della Porta et al., 1967; Flaks, 1968; Dragani et al., 1984, 1987; Diwan et al., 1986; Drinkwater and Ginsler, 1986), but this is not always the case (Grasso and Hardy, 1975; Hanigan et al., 1988; Dragani et al., 1992). Thus, the interpretation of this endpoint in assessing potential health hazards to humans continues to be the subject of active debate. Studies of molecular and genetic factors that modulate the genesis of mouse liver tumors should enhance our understanding of the relevance of this response following exposure to genotoxic as well as nongenotoxic chemicals. To utilize intelligently animal models as surrogates for human carcinogenesis, the validity of rodent tumor endpoints in assessing potential human health hazards from chemical exposure remains an important issue. One approach has been to understand the animal system itself and the mechanisms by which chemicals induce tumors in the animal model. Information regarding the molecular events associated with tumor induction should make the relevance of results from rodent carcinogenicity studies to human risk easier to assess. Results to date have identified activation of ras proto-oncogenes as one early event and an important factor associated with chemical induction of mouse liver neoplasia (Reynolds et al., 1986, 1987; Wiseman et al., 1986), although ras-independent pathways appear to account for an appreciable proportion of some chemically induced mouse liver tumors (Fox et al., 1990; Buchmann et al., 1991). Available data emphasize the complexity of H-ras activation in murine hepatocarcinogenesis. Not only the genetic background of the mouse but also the dose of the carcinogen may influence significantly the number of tumors containing activated H-ras. Both high sensitivity and low sensitivity strains of mice can develop liver tumors which contain activated H-ras oncogenes, showing that the ability to activate this gene does not in itself determine susceptibility to hepatocarcinogenesis. Ras gene mutational profiles in chemically induced liver tumors may be different and distinguishable from those in spontaneous tumors. Since multiple genetic as well as nongenetic events are associated with tumor development, defining a precise role for ras gene mutations when they occur in mouse liver tumors is often difficult.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7676462     DOI: 10.1016/0300-483x(95)03112-s

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  28 in total

1.  Global gene profiling of spontaneous hepatocellular carcinoma in B6C3F1 mice: similarities in the molecular landscape with human liver cancer.

Authors:  Mark J Hoenerhoff; Arun R Pandiri; Stephanie A Lahousse; Hu-Hua Hong; Tai-Vu Ton; Tiwanda Masinde; Scott S Auerbach; Kevin Gerrish; Pierre R Bushel; Keith R Shockley; Shyamal D Peddada; Robert C Sills
Journal:  Toxicol Pathol       Date:  2011-05-13       Impact factor: 1.902

2.  ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.

Authors:  Stephanie E Busch; Kay E Gurley; Russell D Moser; Christopher J Kemp
Journal:  J Pathol       Date:  2012-05-08       Impact factor: 7.996

3.  Chronic administration of ethanol leads to an increased incidence of hepatocellular adenoma by promoting H-ras-mutated cells.

Authors:  Emmanuelle Jeannot; Igor P Pogribny; Frederick A Beland; Ivan Rusyn
Journal:  Cancer Lett       Date:  2010-12-17       Impact factor: 8.679

4.  Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells.

Authors:  M Arsura; F Mercurio; A L Oliver; S S Thorgeirsson; G E Sonenshein
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

5.  Tumorigenicity of acrylamide and its metabolite glycidamide in the neonatal mouse bioassay.

Authors:  Linda S Von Tungeln; Daniel R Doerge; Gonçalo Gamboa da Costa; M Matilde Marques; William M Witt; Igor Koturbash; Igor P Pogribny; Frederick A Beland
Journal:  Int J Cancer       Date:  2012-03-28       Impact factor: 7.396

6.  Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.

Authors:  Marxa L Figueiredo; Timothy J Stein; Adam Jochem; Eric P Sandgren
Journal:  Liver Int       Date:  2012-01-03       Impact factor: 5.828

7.  Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic Mice.

Authors:  Zhuona Rong; Tingting Fan; Huiling Li; Juan Li; Kangwei Wang; Xinxin Wang; Jianyi Dong; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Mol Cell Proteomics       Date:  2017-05-16       Impact factor: 5.911

8.  Hepatocellular carcinomas in B6C3F1 mice treated with Ginkgo biloba extract for two years differ from spontaneous liver tumors in cancer gene mutations and genomic pathways.

Authors:  Mark J Hoenerhoff; Arun R Pandiri; Stephanie A Snyder; Hue-Hua L Hong; Thai-Vu Ton; Shyamal Peddada; Keith Shockley; Kristine Witt; Po Chan; Cynthia Rider; Linda Kooistra; Abraham Nyska; Robert C Sills
Journal:  Toxicol Pathol       Date:  2012-12-21       Impact factor: 1.902

9.  Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from B6C3F1 mice exposed to cumene.

Authors:  Hue-Hua L Hong; Thai-Vu T Ton; Yongbaek Kim; Nobuko Wakamatsu; Natasha P Clayton; Po-Chuen Chan; Robert C Sills; Stephanie A Lahousse
Journal:  Toxicol Pathol       Date:  2008-07-22       Impact factor: 1.902

10.  Carcinogenic ability of Schistosoma haematobium possibly through oncogenic mutation of KRAS gene.

Authors:  Mónica C Botelho; Isabel Veiga; Paula A Oliveira; Carlos Lopes; Manuel Teixeira; José M Correia da Costa; José C Machado
Journal:  Adv Cancer Res Treat       Date:  2013-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.